A New Direction in the Treatment of IBD Patients

Explore the science Contact us

Inflammatory Bowel Disease includes Crohn's disease and ulcerative colitis and affects an estimated 19 million people worldwide.

~19 million

Inflammatory Bowel Disease (IBD)

~7 million

Crohn's disease (CD)

~10 million

Ulcerative colitis (UC)

Estimate: pooled global prevalence × 2025 world population.
Sources: Heydari K, et al. Gastroenterol Hepatol Bed Bench 2025;18(2):132-146. UN World Population Prospects 2024.

Current therapies lack robust efficacy and present adverse safety effects

IBD involves multiple drivers of inflammation. As a result, highly specific therapies fail to achieve durable remission or lose response over time, leading to continuation of symptoms (urgency, pain, and fatigue).

Highly specific therapies also present safety challenges and serious side effects, including Black Box warnings listing serious infections, malignancies, hepatotoxicity, and cardiovascular risks.

>50%

of patients fail to reach remission on current advanced therapies at 1 year

>30%

of patients lose response or remain symptomatic (urgency, pain and fatigue)

Sources: Reves J, et al. Curr Res Pharmacol Drug Discov 2021;2:100070. Qiu Y, et al. J Gastroenterol 2017;52:535-554. Fairbrass KM, et al. Lancet Gastroenterol Hepatol 2020;5(12):1053-1062.

APX3330 is a first-in-class, oral agent targeting the Ref-1 pathway

Ref-1 regulates the activity of several transcription factors and works upstream of known targets involved in inflammation.

APX3330 inhibits the inflammatory response of the Ref-1 pathway, providing the potential to modulate multiple inflammatory pathways involved in IBD.

APX3330 (Ref-1 inhibitor) Oral tablet Convenient and Accessible Oral Tablet Attractive Safety Profile Preservation of Immune Response Mucosal Barrier Integrity Pain and Bowel Urgency Reduction Broad Acting Anti-inflammatory APX3330 (Ref-1 inhibitor) Oral tablet 1 2 3 4 5 6
  1. Convenient and Accessible Oral Tablet1
  2. Attractive Safety Profile2
  3. Preservation of Immune Response3
  4. Mucosal Barrier Integrity4
  5. Pain and Bowel Urgency Reduction5
  6. Broad Acting Anti-inflammatory6

Expected profile if approved.

More about Apexian

Interested in learning more?

Contact our team for investor, partnership and clinical inquiries, or explore our published science.

Contact us View publications